Stay updated on Pembrolizumab IV vs SC with Platinum Doublet Chemo in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab IV vs SC with Platinum Doublet Chemo in NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab IV vs SC with Platinum Doublet Chemo in NSCLC Clinical Trial page
- CheckyesterdayChange DetectedThe site revision identifier was updated from v3.8.0 to v3.8.1.SummaryDifference0.1%

- Check8 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe footer’s website revision identifier changes from v3.7.2 to v3.8.0, reflecting a platform release update.SummaryDifference0.1%

- Check29 days agoChange DetectedA site-wide NIH notice appears above the study record, announcing a website transition and the use of “Super Intelligence” in place of “Artificial Intelligence” during the transition.SummaryDifference0.4%

- Check36 days agoChange DetectedThe ClinicalTrials.gov site footer now displays revision v3.7.2 instead of v3.7.1.SummaryDifference0.1%

- Check43 days agoChange DetectedThe study is now marked **Completed**, replacing its previous **Active, not recruiting** status. A new record version dated 2026-10-07 also logs updates to study identification, recruitment status, study status, and IPD sharing.SummaryDifference0.5%

- Check64 days agoChange DetectedAn updated revision entry, Revision: v3.7.0, was added to the study record history, indicating a new version of the record. The previous revision, Revision: v3.6.6, was removed as part of this update.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab IV vs SC with Platinum Doublet Chemo in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab IV vs SC with Platinum Doublet Chemo in NSCLC Clinical Trial page.